Skip to main content

Table 2 Drug-pathway association in the DTPN of luminal B subtype

From: In silico identification of drug target pathways in breast cancer subtypes using pathway cross-talk inhibition

Drug Pathway nNE and PCI (vs NE = 0.3272)
Docetaxel Germ cell-sertoli cell junction signaling (1); epithelial adherens junction signaling (2) (1) 0.3256 (PCI 0.46%)
(2) 0.3196 (PCI 2.30%)
(1–2) 0.3180 (PCI 2.80%)
Fulvestrant Estrogen-mediated S-phase entry 0.327093 (PCI 0.03%)
Raloxifene Estrogen-mediated S-phase entry 0.327093 (PCI 0.03%)
Tamoxifen Wnt/catenin signaling (1); regulation of the epithelial-mesenchymal transition pathway (2); estrogen-mediated S-phase entry (3) (1) 0.3254 (PCI 0.53%)
(2) 0.3201 (PCI 2.14%)
(3) 0.3270 (PCI 0.03%)
(1–2) 0.3182 (PCI 2.73%)
(1–3) 0.3251 (PCI 0.64%)
(3–2) 0.3196 (PCI 2.29%)
(1–2–3) 0.3174 (PCI 3.06%)
\